Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 10/2010

01.10.2010 | Original Paper

Differential proteomic analysis of a highly metastatic variant of human breast cancer cells using two-dimensional differential gel electrophoresis

verfasst von: Si-Guang Xu, Pei-Jun Yan, Zhi-Ming Shao

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 10/2010

Einloggen, um Zugang zu erhalten

Abstract

Distant metastasis represents the major lethal cause of breast cancer. To understand the molecular mechanisms of breast cancer metastasis and identify markers with metastatic potential, we established a highly metastatic variant of parental MDA-MB-231 cells (MDA-MB-231HM). Using two-dimensional electrophoresis (2-DE), we performed a proteomic comparison of the two kinds of cells. As much as 51 protein spots were differentially expressed between the selected variant and its parental counterpart in at least 3 experiments. Ten unique proteins were identified using matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry (MS), liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS), and database searching software. Among them, nine proteins were up-regulated in MDA-MB-231HM cells, including Macrophage-capping protein (CapG), Galectin-1, Chloride intracellular channel protein 1, Endoplasmic reticulum protein ERp29 precursor, Stathmin-1 (STMN1), Isoform 1 of uridine–cytidine kinase 2(UCK2), Rho GDP-dissociation inhibitor 2 (ARHGDIB), isocitrate dehydrogenase [NADP] cytoplasmic (IDH1), and N-myc downstream regulated gene 1 (NDRG1) protein. Only transgelin-2 was down-regulated. Differential expression was confirmed for three proteins including CapG, STMN1, and transgelin-2 by Western blotting analysis. Transgelin-2 was chosen for further verification by immunohistochemistry. The results suggested that 2-DE would be an efficient way to screen the proteins responsible for specific biological function. Furthermore, the findings imply that different proteins may be involved in the metastatic process in breast carcinomas.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Ahn J, Murphy M, Kratowicz S, Wang A, Levine AJ, George DL (1999) Down-regulation of the stathmin/Op18 and FKBP25 genes following p53 induction. Oncogene 18:5954–5958CrossRefPubMed Ahn J, Murphy M, Kratowicz S, Wang A, Levine AJ, George DL (1999) Down-regulation of the stathmin/Op18 and FKBP25 genes following p53 induction. Oncogene 18:5954–5958CrossRefPubMed
Zurück zum Zitat Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN (1987) A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 47:3239–3245PubMed Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN (1987) A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 47:3239–3245PubMed
Zurück zum Zitat Baldassarre G, Belletti B, Nicoloso MS, Schiappacassi M, Vecchione A, Spessotto P, Morrione A, Canzonieri V, Colombatti A (2005) p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell 7:51–63CrossRefPubMed Baldassarre G, Belletti B, Nicoloso MS, Schiappacassi M, Vecchione A, Spessotto P, Morrione A, Canzonieri V, Colombatti A (2005) p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell 7:51–63CrossRefPubMed
Zurück zum Zitat Belmont LD, Mitchison TJ (1996) Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules. Cell 84:623–631CrossRefPubMed Belmont LD, Mitchison TJ (1996) Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules. Cell 84:623–631CrossRefPubMed
Zurück zum Zitat Blackstock WP, Weir MP (1999) Proteomics: quantitative and physical mapping of cellular proteins. Trends Biotechnol 17:121–127CrossRefPubMed Blackstock WP, Weir MP (1999) Proteomics: quantitative and physical mapping of cellular proteins. Trends Biotechnol 17:121–127CrossRefPubMed
Zurück zum Zitat Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254CrossRefPubMed Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254CrossRefPubMed
Zurück zum Zitat Brattsand G, Roos G, Marklund U, Ueda H, Landberg G, Nånberg E, Sideras P, Gullberg M (1993) Quantitative analysis of the expression and regulation of an activation-regulated phosphoprotein (oncoprotein 18) in normal and neoplastic cells. Leukemia 7:569–579PubMed Brattsand G, Roos G, Marklund U, Ueda H, Landberg G, Nånberg E, Sideras P, Gullberg M (1993) Quantitative analysis of the expression and regulation of an activation-regulated phosphoprotein (oncoprotein 18) in normal and neoplastic cells. Leukemia 7:569–579PubMed
Zurück zum Zitat Budde PP, Kumagai A, Dunphy WG, Heald R (2001) Regulation of Op18 during spindle assembly in Xenopus egg extracts. J Cell Biol 153:149–158CrossRefPubMed Budde PP, Kumagai A, Dunphy WG, Heald R (2001) Regulation of Op18 during spindle assembly in Xenopus egg extracts. J Cell Biol 153:149–158CrossRefPubMed
Zurück zum Zitat Cangul H (2004) Hypoxia upregulates the expression of the NDRG1 gene leading to its overexpression in various human cancers. BMC Genet 5:27CrossRefPubMed Cangul H (2004) Hypoxia upregulates the expression of the NDRG1 gene leading to its overexpression in various human cancers. BMC Genet 5:27CrossRefPubMed
Zurück zum Zitat Cangul H, Salnikow K, Yee H, Zagzag D, Commes T, Costa M (2002) Enhanced overexpression of an HIF-1/hypoxia-related protein in cancer cells. Environ Health Perspect 110:783–788PubMed Cangul H, Salnikow K, Yee H, Zagzag D, Commes T, Costa M (2002) Enhanced overexpression of an HIF-1/hypoxia-related protein in cancer cells. Environ Health Perspect 110:783–788PubMed
Zurück zum Zitat Christgen M, Lehmann U (2007) MDA-MB-435: the questionable use of a melanoma cell line as a model for human breast cancer is ongoing. Cancer Biol Ther 6:1355–1357CrossRefPubMed Christgen M, Lehmann U (2007) MDA-MB-435: the questionable use of a melanoma cell line as a model for human breast cancer is ongoing. Cancer Biol Ther 6:1355–1357CrossRefPubMed
Zurück zum Zitat Curmi PA, Noguès C, Lachkar S, Carelle N, Gonthier MP, Sobel A, Lidereau R, Bièche I (2000) Overexpression of stathmin in breast carcinomas points out to highly proliferative tumours. Br J Cancer 82:142–150CrossRefPubMed Curmi PA, Noguès C, Lachkar S, Carelle N, Gonthier MP, Sobel A, Lidereau R, Bièche I (2000) Overexpression of stathmin in breast carcinomas points out to highly proliferative tumours. Br J Cancer 82:142–150CrossRefPubMed
Zurück zum Zitat Dahl E, Sadr-Nabavi A, Klopocki E, Betz B, Grube S, Kreutzfeld R, Himmelfarb M, An HX, Gelling S, Klaman I, Hinzmann B, Kristiansen G, Grützmann R, Kuner R, Petschke B, Rhiem K, Wiechen K, Sers C, Wiestler O, Schneider A, Höfler H, Nährig J, Dietel M, Schäfer R, Rosenthal A, Schmutzler R, Dürst M, Meindl A, Niederacher D (2005) Systematic identification and molecular characterization of genes differentially expressed in breast and ovarian cancer. J Pathol 205:21–28CrossRefPubMed Dahl E, Sadr-Nabavi A, Klopocki E, Betz B, Grube S, Kreutzfeld R, Himmelfarb M, An HX, Gelling S, Klaman I, Hinzmann B, Kristiansen G, Grützmann R, Kuner R, Petschke B, Rhiem K, Wiechen K, Sers C, Wiestler O, Schneider A, Höfler H, Nährig J, Dietel M, Schäfer R, Rosenthal A, Schmutzler R, Dürst M, Meindl A, Niederacher D (2005) Systematic identification and molecular characterization of genes differentially expressed in breast and ovarian cancer. J Pathol 205:21–28CrossRefPubMed
Zurück zum Zitat Ding SJ, Li Y, Tan YX, Jiang MR, Tian B, Liu YK, Shao XX, Ye SL, Wu JR, Zeng R, Wang HY, Tang ZY, Xia QC (2004) From proteomic analysis to clinical significance: overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis. Mol Cell Proteomics 3:73–81PubMed Ding SJ, Li Y, Tan YX, Jiang MR, Tian B, Liu YK, Shao XX, Ye SL, Wu JR, Zeng R, Wang HY, Tang ZY, Xia QC (2004) From proteomic analysis to clinical significance: overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis. Mol Cell Proteomics 3:73–81PubMed
Zurück zum Zitat Ellen TP, Ke Q, Zhang P, Costa M (2008) NDRG1, a growth and cancer related gene: regulation of gene expression and function in normal and disease states. Carcinogenesis 29:2–8CrossRefPubMed Ellen TP, Ke Q, Zhang P, Costa M (2008) NDRG1, a growth and cancer related gene: regulation of gene expression and function in normal and disease states. Carcinogenesis 29:2–8CrossRefPubMed
Zurück zum Zitat Ellison G, Klinowska T, Westwood RF, Docter E, French T, Fox JC (2002) Further evidence to support the melanocytic origin of MDA-MB-435. Mol Pathol 55:294–299CrossRefPubMed Ellison G, Klinowska T, Westwood RF, Docter E, French T, Fox JC (2002) Further evidence to support the melanocytic origin of MDA-MB-435. Mol Pathol 55:294–299CrossRefPubMed
Zurück zum Zitat Feng JT, Liu YK, Song HY, Dai Z, Qin LX, Almofti MR, Fang CY, Lu HJ, Yang PY, Tang ZY (2005) Heat-shock protein 27: a potential biomarker for hepatocellular carcinoma identified by serum proteome analysis. Proteomics 5:4581–4588CrossRefPubMed Feng JT, Liu YK, Song HY, Dai Z, Qin LX, Almofti MR, Fang CY, Lu HJ, Yang PY, Tang ZY (2005) Heat-shock protein 27: a potential biomarker for hepatocellular carcinoma identified by serum proteome analysis. Proteomics 5:4581–4588CrossRefPubMed
Zurück zum Zitat Fisher B, Dignam J, Bryant J, Wolmark N (2001) Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93:684–690CrossRefPubMed Fisher B, Dignam J, Bryant J, Wolmark N (2001) Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93:684–690CrossRefPubMed
Zurück zum Zitat Gildea JJ, Seraj MJ, Oxford G, Harding MA, Hampton GM, Moskaluk CA, Frierson HF, Conaway MR, Theodorescu D (2002) RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res 62:6418–6423PubMed Gildea JJ, Seraj MJ, Oxford G, Harding MA, Hampton GM, Moskaluk CA, Frierson HF, Conaway MR, Theodorescu D (2002) RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res 62:6418–6423PubMed
Zurück zum Zitat Hou YF, Yuan ST, Li HC, Wu J, Lu JS, Liu G, Lu LJ, Shen ZZ, Ding J, Shao ZM (2004) ERbeta exerts multiple stimulative effects on human breast carcinoma cells. Oncogene 23:5799–5806CrossRefPubMed Hou YF, Yuan ST, Li HC, Wu J, Lu JS, Liu G, Lu LJ, Shen ZZ, Ding J, Shao ZM (2004) ERbeta exerts multiple stimulative effects on human breast carcinoma cells. Oncogene 23:5799–5806CrossRefPubMed
Zurück zum Zitat Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS, ATAC Trialists’ Group (2005) Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62CrossRefPubMed Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS, ATAC Trialists’ Group (2005) Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62CrossRefPubMed
Zurück zum Zitat Hurst DR, Xie Y, Vaidya KS, Mehta A, Moore BP, Accavitti-Loper MA, Samant RS, Saxena R, Silveira AC, Welch DR (2008) Alterations of BRMS1–ARID4A interaction modify gene expression but still suppress metastasis in human breast cancer cells. J Biol Chem 283:7438–7444CrossRefPubMed Hurst DR, Xie Y, Vaidya KS, Mehta A, Moore BP, Accavitti-Loper MA, Samant RS, Saxena R, Silveira AC, Welch DR (2008) Alterations of BRMS1–ARID4A interaction modify gene expression but still suppress metastasis in human breast cancer cells. J Biol Chem 283:7438–7444CrossRefPubMed
Zurück zum Zitat Keller A, Nesvizhskii AI, Kolker E, Aebersold R (2002) Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 74:5383–5392CrossRefPubMed Keller A, Nesvizhskii AI, Kolker E, Aebersold R (2002) Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 74:5383–5392CrossRefPubMed
Zurück zum Zitat Kurdistani SK, Arizti P, Reimer CL, Sugrue MM, Aaronson SA, Lee SW (1998) Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage. Cancer Res 58:4439–4444PubMed Kurdistani SK, Arizti P, Reimer CL, Sugrue MM, Aaronson SA, Lee SW (1998) Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage. Cancer Res 58:4439–4444PubMed
Zurück zum Zitat Lachat P, Shaw P, Gebhard S, van Belzen N, Chaubert P, Bosman FT (2002) Expression of NDRG1, a differentiation-related gene, in human tissues. Histochem Cell Biol 118:399–408CrossRefPubMed Lachat P, Shaw P, Gebhard S, van Belzen N, Chaubert P, Bosman FT (2002) Expression of NDRG1, a differentiation-related gene, in human tissues. Histochem Cell Biol 118:399–408CrossRefPubMed
Zurück zum Zitat Lal A, Lash AE, Altschul SF, Velculescu V, Zhang L, McLendon RE, Marra MA, Prange C, Morin PJ, Polyak K, Papadopoulos N, Vogelstein B, Kinzler KW, Strausberg RL, Riggins GJ (1999) A public database for gene expression in human cancers. Cancer Res 59:5403–5407PubMed Lal A, Lash AE, Altschul SF, Velculescu V, Zhang L, McLendon RE, Marra MA, Prange C, Morin PJ, Polyak K, Papadopoulos N, Vogelstein B, Kinzler KW, Strausberg RL, Riggins GJ (1999) A public database for gene expression in human cancers. Cancer Res 59:5403–5407PubMed
Zurück zum Zitat Li DQ, Wang L, Fei F, Hou YF, Luo JM, Wei-Chen, Zeng R, Wu J, Lu JS, Di GH, Ou ZL, Xia QC, Shen ZZ, Shao ZM (2006) Identification of breast cancer metastasis-associated proteins in an isogenic tumor metastasis model using two-dimensional gel electrophoresis and liquid chromatography-ion trap-mass spectrometry. Proteomics 6:3352–3368CrossRefPubMed Li DQ, Wang L, Fei F, Hou YF, Luo JM, Wei-Chen, Zeng R, Wu J, Lu JS, Di GH, Ou ZL, Xia QC, Shen ZZ, Shao ZM (2006) Identification of breast cancer metastasis-associated proteins in an isogenic tumor metastasis model using two-dimensional gel electrophoresis and liquid chromatography-ion trap-mass spectrometry. Proteomics 6:3352–3368CrossRefPubMed
Zurück zum Zitat Li M, Li S, Lou Z, Liao X, Zhao X, Meng Z, Bartlam M, Rao Z (2008) Crystal structure of human transgelin. J Struct Biol 162:229–236CrossRefPubMed Li M, Li S, Lou Z, Liao X, Zhao X, Meng Z, Bartlam M, Rao Z (2008) Crystal structure of human transgelin. J Struct Biol 162:229–236CrossRefPubMed
Zurück zum Zitat Liu YF, Xiao ZQ, Li MX, Li MY, Zhang PF, Li C, Li F, Chen YH, Yi H, Yao HX, Chen ZC (2009) Quantitative proteome analysis reveals annexin A3 as a novel biomarker in lung adenocarcinoma. J Pathol 217:54–64CrossRefPubMed Liu YF, Xiao ZQ, Li MX, Li MY, Zhang PF, Li C, Li F, Chen YH, Yi H, Yao HX, Chen ZC (2009) Quantitative proteome analysis reveals annexin A3 as a novel biomarker in lung adenocarcinoma. J Pathol 217:54–64CrossRefPubMed
Zurück zum Zitat Luo XN, Mookerjee B, Ferrari A, Mistry S, Atweh GF (1994) Regulation of phosphoprotein p18 in leukemic cells. Cell cycle regulated phosphorylation by p34cdc2 kinase. J Biol Chem 269:10312–10318PubMed Luo XN, Mookerjee B, Ferrari A, Mistry S, Atweh GF (1994) Regulation of phosphoprotein p18 in leukemic cells. Cell cycle regulated phosphorylation by p34cdc2 kinase. J Biol Chem 269:10312–10318PubMed
Zurück zum Zitat Nair RR, Solway J, Boyd DD (2006) Expression cloning identifies transgelin (SM22) as a novel repressor of 92-kDa type IV collagenase (MMP-9) expression. J Biol Chem 281:26424–26436CrossRefPubMed Nair RR, Solway J, Boyd DD (2006) Expression cloning identifies transgelin (SM22) as a novel repressor of 92-kDa type IV collagenase (MMP-9) expression. J Biol Chem 281:26424–26436CrossRefPubMed
Zurück zum Zitat Nesvizhskii AI, Keller A, Kolker E, Aebersold R (2003) A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 75:4646–4658CrossRefPubMed Nesvizhskii AI, Keller A, Kolker E, Aebersold R (2003) A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 75:4646–4658CrossRefPubMed
Zurück zum Zitat Nishio S, Ushijima K, Tsuda N, Takemoto S, Kawano K, Yamaguchi T, Nishida N, Kakuma T, Tsuda H, Kasamatsu T, Sasajima Y, Kage M, Kuwano M, Kamura T (2008) Cap43/NDRG1/Drg-1 is a molecular target for angiogenesis and a prognostic indicator in cervical adenocarcinoma. Cancer Lett 264:36–43CrossRefPubMed Nishio S, Ushijima K, Tsuda N, Takemoto S, Kawano K, Yamaguchi T, Nishida N, Kakuma T, Tsuda H, Kasamatsu T, Sasajima Y, Kage M, Kuwano M, Kamura T (2008) Cap43/NDRG1/Drg-1 is a molecular target for angiogenesis and a prognostic indicator in cervical adenocarcinoma. Cancer Lett 264:36–43CrossRefPubMed
Zurück zum Zitat Nylander K, Marklund U, Brattsand G, Gullberg M, Roos G (1995) Immunohistochemical detection of oncoprotein 18 (Op18) in malignant lymphomas. Histochem J 27:155–160CrossRefPubMed Nylander K, Marklund U, Brattsand G, Gullberg M, Roos G (1995) Immunohistochemical detection of oncoprotein 18 (Op18) in malignant lymphomas. Histochem J 27:155–160CrossRefPubMed
Zurück zum Zitat Onoda K, Yu FX, Yin HL (1993) gCap39 is a nuclear and cytoplasmic protein. Cell Motil Cytoskelet 26:227–238CrossRef Onoda K, Yu FX, Yin HL (1993) gCap39 is a nuclear and cytoplasmic protein. Cell Motil Cytoskelet 26:227–238CrossRef
Zurück zum Zitat Pollard TD, Borisy GG (2003) Cellular motility driven by assembly and disassembly of actin filaments. Cell 112:453–465CrossRefPubMed Pollard TD, Borisy GG (2003) Cellular motility driven by assembly and disassembly of actin filaments. Cell 112:453–465CrossRefPubMed
Zurück zum Zitat Price DK, Ball JR, Bahrani-Mostafavi Z, Vachris JC, Kaufman JS, Naumann RW, Higgins RV, Hall JB (2000) The phosphoprotein Op18/stathmin is differentially expressed in ovarian cancer. Cancer Invest 18:722–730CrossRefPubMed Price DK, Ball JR, Bahrani-Mostafavi Z, Vachris JC, Kaufman JS, Naumann RW, Higgins RV, Hall JB (2000) The phosphoprotein Op18/stathmin is differentially expressed in ovarian cancer. Cancer Invest 18:722–730CrossRefPubMed
Zurück zum Zitat Rae JM, Ramus SJ, Waltham M, Armes JE, Campbell IG, Clarke R, Barndt RJ, Johnson MD, Thompson EW (2004) Common origins of MDA-MB-435 cells from various sources with those shown to have melanoma properties. Clin Exp Metastasis 21:543–552CrossRefPubMed Rae JM, Ramus SJ, Waltham M, Armes JE, Campbell IG, Clarke R, Barndt RJ, Johnson MD, Thompson EW (2004) Common origins of MDA-MB-435 cells from various sources with those shown to have melanoma properties. Clin Exp Metastasis 21:543–552CrossRefPubMed
Zurück zum Zitat Rae JM, Creighton CJ, Meck JM, Haddad BR, Johnson MD (2007) MDA-MB-435 cells are derived from M14 melanoma cells–a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat 104:13–19CrossRefPubMed Rae JM, Creighton CJ, Meck JM, Haddad BR, Johnson MD (2007) MDA-MB-435 cells are derived from M14 melanoma cells–a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat 104:13–19CrossRefPubMed
Zurück zum Zitat Rana S, Maples PB, Senzer N, Nemunaitis J (2008) Stathmin 1: a novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther 8:1461–1470CrossRefPubMed Rana S, Maples PB, Senzer N, Nemunaitis J (2008) Stathmin 1: a novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther 8:1461–1470CrossRefPubMed
Zurück zum Zitat Renz M, Betz B, Niederacher D, Bender HG, Langowski J (2008) Invasive breast cancer cells exhibit increased mobility of the actin-binding protein CapG. Int J Cancer 122:1476–1482CrossRefPubMed Renz M, Betz B, Niederacher D, Bender HG, Langowski J (2008) Invasive breast cancer cells exhibit increased mobility of the actin-binding protein CapG. Int J Cancer 122:1476–1482CrossRefPubMed
Zurück zum Zitat Rowlands DC, Williams A, Jones NA, Guest SS, Reynolds GM, Barber PC, Brown G (1995) Stathmin expression is a feature of proliferating cells of most, if not all, cell lineages. Lab Invest 72:100–113PubMed Rowlands DC, Williams A, Jones NA, Guest SS, Reynolds GM, Barber PC, Brown G (1995) Stathmin expression is a feature of proliferating cells of most, if not all, cell lineages. Lab Invest 72:100–113PubMed
Zurück zum Zitat Schunke D, Span P, Ronneburg H, Dittmer A, Vetter M, Holzhausen HJ, Kantelhardt E, Krenkel S, Müller V, Sweep FC, Thomssen C, Dittmer J (2007) Cyclooxygenase-2 is a target gene of rho GDP dissociation inhibitor beta in breast cancer cells. Cancer Res 67:10694–10702CrossRefPubMed Schunke D, Span P, Ronneburg H, Dittmer A, Vetter M, Holzhausen HJ, Kantelhardt E, Krenkel S, Müller V, Sweep FC, Thomssen C, Dittmer J (2007) Cyclooxygenase-2 is a target gene of rho GDP dissociation inhibitor beta in breast cancer cells. Cancer Res 67:10694–10702CrossRefPubMed
Zurück zum Zitat Shevchenko A, Wilm M, Vorm O, Mann M (1996) Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 68:850–858CrossRefPubMed Shevchenko A, Wilm M, Vorm O, Mann M (1996) Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 68:850–858CrossRefPubMed
Zurück zum Zitat Thompson CC, Ashcroft FJ, Patel S, Saraga G, Vimalachandran D, Prime W, Campbell F, Dodson A, Jenkins RE, Lemoine NR, Crnogorac-Jurcevic T, Yin HL, Costello E (2007) Pancreatic cancer cells overexpress gelsolin family-capping proteins, which contribute to their cell motility. Gut 56:95–106CrossRefPubMed Thompson CC, Ashcroft FJ, Patel S, Saraga G, Vimalachandran D, Prime W, Campbell F, Dodson A, Jenkins RE, Lemoine NR, Crnogorac-Jurcevic T, Yin HL, Costello E (2007) Pancreatic cancer cells overexpress gelsolin family-capping proteins, which contribute to their cell motility. Gut 56:95–106CrossRefPubMed
Zurück zum Zitat Van Belzen N, Dinjens WN, Diesveld MP, Groen NA, van der Made AC, Nozawa Y, Vlietstra R, Trapman J, Bosman FT (1997) A novel gene which is up-regulated during colon epithelial cell differentiation and down-regulated in colorectal neoplasms. Lab Invest 77:85–92PubMed Van Belzen N, Dinjens WN, Diesveld MP, Groen NA, van der Made AC, Nozawa Y, Vlietstra R, Trapman J, Bosman FT (1997) A novel gene which is up-regulated during colon epithelial cell differentiation and down-regulated in colorectal neoplasms. Lab Invest 77:85–92PubMed
Zurück zum Zitat Van Ginkel PR, Gee RL, Walker TM, Hu DN, Heizmann CW, Polans AS (1998) The identification and differential expression of calcium-binding proteins associated with ocular melanoma. Biochim Biophys Acta 1448:290–297CrossRefPubMed Van Ginkel PR, Gee RL, Walker TM, Hu DN, Heizmann CW, Polans AS (1998) The identification and differential expression of calcium-binding proteins associated with ocular melanoma. Biochim Biophys Acta 1448:290–297CrossRefPubMed
Zurück zum Zitat Weigelt B, Peterse JL, van ‘t Veer LJ (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5:591–602CrossRefPubMed Weigelt B, Peterse JL, van ‘t Veer LJ (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5:591–602CrossRefPubMed
Zurück zum Zitat Yan JX, Wait R, Berkelman T, Harry RA, Westbrook JA, Wheeler CH, Dunn MJ (2000) A modified silver staining protocol for visualization of proteins compatible with matrix-assisted laser desorption/ionization and electrospray ionization-mass spectrometry. Electrophoresis 21:3666–3672CrossRefPubMed Yan JX, Wait R, Berkelman T, Harry RA, Westbrook JA, Wheeler CH, Dunn MJ (2000) A modified silver staining protocol for visualization of proteins compatible with matrix-assisted laser desorption/ionization and electrospray ionization-mass spectrometry. Electrophoresis 21:3666–3672CrossRefPubMed
Zurück zum Zitat Yang Z, Chang YJ, Miyamoto H, Ni J, Niu Y, Chen Z, Chen YL, Yao JL, di Sant’Agnese PA, Chang C (2007) Transgelin functions as a suppressor via inhibition of ARA54-enhanced androgen receptor transactivation and prostate cancer cell growth. Mol Endocrinol 21:343–358CrossRefPubMed Yang Z, Chang YJ, Miyamoto H, Ni J, Niu Y, Chen Z, Chen YL, Yao JL, di Sant’Agnese PA, Chang C (2007) Transgelin functions as a suppressor via inhibition of ARA54-enhanced androgen receptor transactivation and prostate cancer cell growth. Mol Endocrinol 21:343–358CrossRefPubMed
Metadaten
Titel
Differential proteomic analysis of a highly metastatic variant of human breast cancer cells using two-dimensional differential gel electrophoresis
verfasst von
Si-Guang Xu
Pei-Jun Yan
Zhi-Ming Shao
Publikationsdatum
01.10.2010
Verlag
Springer-Verlag
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 10/2010
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-010-0812-0

Weitere Artikel der Ausgabe 10/2010

Journal of Cancer Research and Clinical Oncology 10/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.